YOU MIGHT BE INTERESTED IN

Anti-Obesity Treatments 2007-2012: A blockbuster target market
By 2010, almost 50 percent of children in North America and 38 percent of those in the European Union will be overweight. For pharmaceutical companies looking to target growing successful markets, the anti-obesity drug treatment market offers unique opportunities.
...more details
The World Diabetes Market, 2007-2025: A Key Pharmaceutical Market of the Future
Diabetes affects approximately 246 million people worldwide and this number is increasing. The IDF predict 380 million diabetics by 2025. The Global Diabetes drug treatment market was valued at over $21 billion in 2006 and the market is still expanding rapidly due to the high prevalence of diabetes and lifestyle changes.
...more details
Anti-addiction Therapies, 2006-2011 The Pharmaceutical Industry's Next Viagra?
More money is spent advertising alcohol than any other product. For some, gambling and cigarettes are pleasant distractions, yet for others they are the generators of unbearable cravings and the cause of considerable distress. For them their addition is a disease...
...more details
Cannabinoid Market Forecasts & Analysis to 2012
With 4 drugs now in the marketplace (a 100% rise from 2 years ago), the cannabinoid market continues to grow. Attitudes to the drugs are changing ensuring greater market penetration, and the first cannabinoid blockbuster is now a certainty.
...more details
World market for cancer vaccines 2007-2012
Previously the cancer vaccine market has consisted of HBV (hepatitis B virus) vaccines to prevent liver cancer. 2006 saw the launch of Gardasil the first vaccine against HPV (human papilloma virus) to protect against cervical cancer. Another HPV vaccine, Cervarix, is due to be launched in 2007...
...more details
Tissue Engineering & Stem Cell Technology Report 2007
The market potential of this technology is so huge that revenues may be in excess of $10 billion by 2013. This is a market that you should be part of - NOW!! With a complex regulatory structure still to overcome, yet continued high level investment, many of your competitors are aware of the the commercial opportunities within Tissue Engineering & Stem Cell Technology.
...more details

CONFERENCE

...see all

Colloquium on Obesity Drug Development

Analysing the growing potential for pharmaceuticals to reduce the spread of obesity in a global market

13th - 14th October 2008, BSG Conference Centre, 226 - 236 City Road, London, EC1V 2TT, United Kingdom

Download brochure Products

Background Info
Day 1
Day 2
Partners
Past Papers

Associate Sponsor

Media Partners

Background Info

More than one million prescriptions are being written for obesity drugs in the UK alone, costing £47.5m a year and accounting for nearly 3% of total NHS expenditure. If untreated, obesity and related illnesses can cost many times this amount, so there is understandably a large market for drugs to treat the condition.

In the last decade the obesity epidemic has increased rapidly both in terms of proportion of the affected population of affected countries, but also in the number of countries where there is a cause for concern. Rather than being confined to a handful of developed nations, the disorder now affects many countries worldwide.

If you have not yet taken steps in this direction, or you’d like to know how to improve your chances of securing approval for your new products, our lineup of expert speakers at visiongain’s 2008 Obesity Colloquium will be on hand to share their knowledge and experience. This event promises to bring together leaders in the field, so why not take the time to reserve your place now?

However, the market has encountered mixed fortunes in recent years, and lack of adequate reimbursement could foreseeably limit the potential of anti-obesity drugs. By networking with your peers this October, you will find out what steps need to be taken in order to stay competitive, and also to avoid unexpected setbacks.

Visiongain’s hotly-anticipated event will enable you to examine the latest technological breakthroughs, discuss and debate scientific processes, share expert opinions on all aspects of treatment, and forge the right partnerships for the combating obesity in the coming years.

Key Speakers:
• Dr. Alina Rodriguez, Dept. of Psychology, Uppsala University
• Dr. Jason C.G. Halford, Reader in Appetite and Obesity, Director of the Kissileff Human Ingestive, Behaviour Laboratory School of Psychology, University of Liverpool
• Dr Carel le Roux, Consultant in Metabolic Medicine, Imperial College Healthcare
• Dr. Matthew Coghlan, Candidate Drug Delivery Team Leader, AstraZeneca
• Dr. Hubert C. Chen, Senior Director of Clinical Research, Amylin Pharmaceuticals
• Professor Michael Cawthorne, Director of Metabolic Research & Professorial Research Fellow, University of Buckingham
• Professor John Wilding, Head of Diabetes and Endocrinology Research Unit University Hospital, University Hospital Aintree
• Dr Marie Kunesova, Head of the Obesity Management Centre, Institute of Endocrinology
• Professor David J Heal, Director, RenaSci Consultancy
• Dr Nick Finer, Clinical Director, Wellcome Clinical Research, Addenbrooke’s Hospital
• Dr Donny Wong, Principal Analyst, Cardiovascular and Metabolic Disorders, Decision Resources
• Dr Maria Paula Macedo (Ph.D. Pharm.D.), Department of Physiology, Faculty of Medical Sciences, New University of Lisbon

Key Themes:
• Learn approaches and emerging options for clinical weight management
• Review the effects of obesity on health and well-being of individuals and communities
• Thoroughly assess obesity and its associated comorbidities
• Examine interventions for the prevention of obesity and evaluate performance to date
• Evaluate treatment approaches and clinical practice
• Recognise obesity phenotypes
• Find out the impact of products for appetite regulation
• Discuss the key impact of Iatrogenesis and weight control
• Determine the optimal use of pharmacotherapy in the management of obesity

Who Should Attend?
By organisation:
• Pharmaceutical and Biotechnology Companies
• Contract Organisations
• Sales and Marketing Organisations
• Pharmaceutical Associations
• Technology Suppliers
• Research institutes & Universities
• Development and Manufacturing Organisations
• Medical Affairs

By job title:
• Head of Drug Development Strategy
• Vice President, Diabetes & Obesity, Clinical R&D
• Vice President, Cardiovascular & Metabolic Diseases
• Head, New Antidiabetic Agents
• Senior Director, Endocrinology & Metabolism
• Medical Director, Metabolic Disease Research
• Principle Investigator, Department of Metabolic Disorders
• Chief Scientific Officer
• Director, New Products Global Marketing & Sales
• Director of Nutrition/Dieticians/Education
• VP of Approval / Regulatory Affairs / Consumer Protection

Day 1

09:00 Registration and refreshments

09:30 Opening address from the chair

Dr. Alina Rodriguez
Dept. of Psychology
Uppsala University

09:40 Examining patient need and drug development
• The scale of the obesity problem (numbers, co-morbidity and health costs)
• Medical benefits of weight loss
• The real difficulties people face when trying to lose weight through diet, exercise and behavioural change leading to low rates of success
• Benefits and limitations of current approaches over and above lifestyle change (drugs, surgery)
• The need for new drugs

Professor John Wilding
Head of Diabetes and Endocrinology Research Unit University Hospital
University Hospital Aintree

10.20 The clinical positioning of pharmacotherapy for obesity
• Is there a clinical need for anti-obesity drugs?
• What can drugs add to diet and lifestyle management?
• When should drugs be used to treat obesity?
• When should drugs not be used to treat obesity?

Dr Nick Finer
Clinical Director, Wellcome Clinical Research
Addenbrooke’s Hospital

11:10 Morning refreshments

11:30 Pharmacological targets from understanding the changes in physiology after bariatric surgery
• Peripheral control of appetite- what do we understand from physiology
• Physiological changes after gastric banding
• Physiological changes after gastric bypass
• What can big Pharma learn from bariatric surgery

Dr Carel le Roux
Consultant in Metabolic Medicine
Imperial College Healthcare

12:10 Obesity and type 2 diabetes
• What can be done to prevent/delay type 2 diabetes and to what extent can it be successful
• Current treatment options
• Food intake vs energy expenditure
• What can we learn from GI surgery
• What is in the future?

Dr. Karin Rimvall
Associate Director, Section for Diabetes and Obesity
AstraZeneca

12:50 Networking lunch

14:00 Anti-obesity drugs in the treatment of Type 2 diabetes

Professor Michael Cawthorne
Director of Metabolic Research & Professorial Research Fellow
University of Buckingham

14:40 Introduction to obesity and mental health
• Adiposity and the brain
• Link with emotion and mental health
• Long-term consequences

Dr. Alina Rodriguez
Dept. of Psychology
Uppsala University

15:20 Afternoon refreshments

15:40 Role of diet in obesity management

Dr Marie Kunesova
Head of the Obesity Management Centre
Institute of Endocrinology

16:20 Panel discussion: Comparing Germany, the UK, US, Japan, and developing nations
• Discussing the EU Health Commissioner report that more than half of adults in the EU are currently overweight
• WHO considers obesity to be a worldwide epidemic
• Will the US still have the highest prevalence of obesity in 2015?
• The anti-obesity market in developing nations, and how this affects the global market now and in the future

Dr. Matthew Coghlan*
Candidate Drug Delivery Team Leader
AstraZeneca

17:00 Closing remarks from the chair

17:05 Networking drinks
Take your discussions further and build new relationships in a relaxed and informal setting.

Day 2

09:00 Registration and refreshments

09:30 Opening address from chair

09:40 Old & new examples of obesity therapy – can we get more effective?
• Reimbursement requires significant weight loss or treatment of complications
• Major medical need
• Massive market and significant profit potential
• No block busters yet available
• Nothing very promising in the pipeline

Professor Steve Bloom
Department of Metabolic Medicine
Imperial College London

10:20 Genes associated with “lean phenotype” as targets for obesity treatment.
• Why obesity genes do not deliver an answer for obesity treatment?
• Looking for “lean genes” in lean phenotype.
• How to identify genes associated with lean phenotype

Dr Itzik Harosh
Chairman and Chief Scientist (CSO)
ObeTherapy

11:00 Morning refreshments

11:20 Routes to regulatory approval for metabolic drugs

Professor David J Heal
Director
RenaSci Consultancy

12:00 The pharmaceutical market for obesity drugs
• What are the key drivers and constraints that will shape the future market for obesity drugs?
• What unmet needs must novel therapies address in order to be successful in this market?
• What does primary research tell us about the demands of prescribers?

Dr Donny Wong
Principal Analyst, Cardiovascular and Metabolic Disorders
Decision Resources

12:40 Networking lunch

13:50 Post-prandial insulin sensitivity in obesity: Can it be preserved
• Mechanisms that compose the meal induced insulin sensitivity pathway.
• Can we prevent loosing it with obesity?
• Meal induced insulin sensitivity and its impact on overweight subjects.

Dr Maria Paula Macedo (Ph.D. Pharm.D.)
Department of Physiology, Faculty of Medical Sciences
New University of Lisbon

14:30 Understanding energy intake in the obese and obesogenic behaviour as a pharmacological target
• Is there such as thing as an obesogenic eating style?
• Is appetite regulation different in the obese?
• What are the roles of deficits in satiety or hedonic aspects of eating in obesity?
• Intake and eating behaviour as outcome variables in clinical studies

Dr. Jason C.G. Halford
Reader in Appetite and Obesity, Director of the Kissileff Human Ingestive
Behaviour Laboratory School of Psychology
University of Liverpool

15:10 Afternoon refreshments

15:30 Panel Discussion: Phase 2 trials – a thorough roundup
• Novo Nordisk’s Liraglutide
• Sanofi-Aventis’ Surinabant (SR 147778)
• Pfizer’s CP 741952 and CP 866087
• Alizyme’s Cetilistat (ATL 962)
• Solvay’s SLV 319 (BMS 646256)
• Amylin’s Pramlintide (Symlin, Normylin)
• Kissei’s 869682
• Metabolic’s AOD 9604
• Sanofi-Aventis’ AVE 1625
• Orexigen’s Bupropion/Zonisamide (Empatic/Excalia)

16:00 Pipeline Developments in anti-obesity Treatments
• Genzyme’s GT 389255
• Amgen’s Metreleptin
• VIVUS’ Phentermine/topiramate (MK 0493)
• 7TM Pharma’s TM 30338
• Shionogi’s S 2367
• Obecure’s OBE101
• Discussion of other current pipeline developments

Dr. Hubert C. Chen
Senior Director of Clinical Research
Amylin Pharmaceuticals

16:20 Chair’s closing remarks and end of conference

Partners

Associate Sponsor:

Diabetes UK
Diabetes UK is the largest organisation in the UK working for people with diabetes, funding research, campaigning and helping people live with the condition.

We have over 170,000 members and are working for people with diabetes, their carers, family and friends. We represent the interests of people with diabetes by lobbying the government for better standards of care and the best quality of life.

Our mission is to improve the lives of people with diabetes and to work towards a future without diabetes. For further information please visit: www.diabetes.org.uk

Media Partners:

PharmiWeb.com
PharmiWeb.com is the leading industry-sponsored portal for the pharmaceutical sector. Supported by most of the leading pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news, features, events listings and international jobs to industry professionals across Europe and the US. For further information please email: corporate@pharmiweb.com

BIOTECHNOLOGY EUROPE
BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY WORLD. It is based and located in Warsaw, Poland. Biotechnology World was founded in 2007 to provide the world’s biotech and pharma information and market to make it universally accessible and useful for scientific and business processes. Its first step to fulfilling that mission was building the BIOTECHNOLOGY EUROPE platform that will allow a quick spread of information in different channels. BIOTECHNOLOGY EUROPE offers companies completed internet public relations, publication and marketing solutions. One of the mains goals of BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to global biotechnology, pharmaceutical and life science activities. For further information please visit www.biotechnology-europe.com

Espicom
Espicom has been a respected provider of pharmaceutical information for over 25 years. Over twenty titles/services span the industry from comprehensive newsletters in key areas such as cancer drugs, drug delivery and generics to in-depth company/market reports. Espicom’s specialist online services are used daily by leading manufacturers and service companies. For further information please visit: www.espicom.com

Cardiovascular Drug News
Cardiovascular Drug News is the leading monthly business publication from Espicom Business Intelligence that keeps industry executives in touch with the market for drugs treating all conditions of the heart and circulatory system. For further information please visit: www.espicom.com/cvdn

The Association for the Study of Obesity
The Association for the Study of Obesity (ASO) is the UK's foremost organisation dedicated to the understanding, prevention and treatment of obesity. Founded in 1967, the Association was the first such organisation worldwide and is affiliated to the European (EASO) and International (IASO) Associations for the Study of Obesity. Its members consist primarily of health professionals and academics who work in the field of obesity and weight management.

Our mission is:
• To promote professional awareness of obesity and its impact on health.
• To educate and disseminate recent research on the causes, consequences, treatment, and prevention of obesity.
• To prioritise obesity and provide opinion leadership in the UK.

We do this through our conferences, training programmes, and work with external bodies such as the media, government bodies, food and biotech industries. Contact: Ms Chris Hawkins, Administrative Officer, Association for the Study of Obesity, 20 Brook Meadow Close, Wood Green, Essex, IG8 9NR. Tel: 0208 503 2042. E-Mail: chris@aso.ndo.co.uk. Website: www.aso.org.uk

If you would like information on the range of sponsorship or exhibition possibilities for this conference, please contact:

Sara Mathieson: +44 (0)207 75499948

Past Papers

Past papers are free to delegates. If you are unable to attend the event, Past Papers are published two weeks after the event and are available to purchase.

Buy Now

YOU MIGHT BE INTERESTED IN

Anti-Obesity Treatments 2007-2012: A blockbuster target market

The World Diabetes Market, 2007-2025: A Key Pharmaceutical Market of the Future

Anti-addiction Therapies, 2006-2011 The Pharmaceutical Industry's Next Viagra?

Cannabinoid Market Forecasts & Analysis to 2012

World market for cancer vaccines 2007-2012

Tissue Engineering & Stem Cell Technology Report 2007